Dienogest and the breast.
In a clinical pilot study, 21 women with endometriosis have been primarely treated with dienogest 2 x 10 mg daily p.o. for 24 weeks. Besides the effect on endometriosis the action of such high-dose progestogen treatment on the breast was evaluated by breast ultrasound prior to medication and at 24 weeks of medical treatment. In all women, a significant size reduction of the mammary gland (p < 0.023) and regression of mastopathic changes were observed. There was a non-significant reduction (p = 0.089) of the maximum diameter of the ducts. The portion of the fatty tissue increased slightly, but not significantly (p = 0.348).
Schindler
Adolf E
AE
Institute for Medical Research and Education, Hufelandstrasse 55, D-45122 Essen, Germany. adolf.schindler@uni-due.de
Henkel
Alexandria
A
Christensen
Bernd
B
Oettel
Michel
M
Moore
Claudia
C
D000328:Adult; D001940:Breast / Q000187:drug effects*; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D005348:Fibrocystic Breast Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006727:Hormone Antagonists / Q000008:administration & dosage*; D006801:Humans; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010865:Pilot Projects; D016217:Ultrasonography, Mammary; D055815:Young Adult
D006727:Hormone Antagonists; C023635:dienogest; D009277:Nandrolone